Novartis AG (NVS)
| Market Cap | 280.78B +27.3% |
| Revenue (ttm) | 56.58B +6.3% |
| Net Income | 13.53B +5.2% |
| EPS | 6.98 +9.5% |
| Shares Out | 1.91B |
| PE Ratio | 20.75 |
| Forward PE | 16.66 |
| Dividend | $3.08 (2.01%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 1,178,040 |
| Open | 153.93 |
| Previous Close | 153.92 |
| Day's Range | 152.85 - 154.22 |
| 52-Week Range | 112.34 - 170.46 |
| Beta | 0.49 |
| Analysts | Hold |
| Price Target | 153.87 (+0.52%) |
| Earnings Date | Jul 16, 2026 |
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $153.87, which is an increase of 0.52% from the latest price.
News
Novartis (NVS) Advances RNA Therapy Del-Brax in FSHD Trials
Novartis (NVS) Advances RNA Therapy Del-Brax in FSHD Trials
Novartis (NVS) Achieves Key Milestone with Rhapsido in CIndU Trial
Novartis (NVS) Achieves Key Milestone with Rhapsido in CIndU Trial
Novartis' Rhapsido Shows Promise In Chronic Inducible Urticaria
(RTTNews) - Novartis (NVS) unveiled late-breaking Phase 3 RemIND trial data at the EAACI Congress, highlighting the potential of Rhapsido (remibrutinib) as the first targeted therapy for chronic induc...
Novartis announces Rhapsido met primary endpoints in RemIND trial
Novartis (NVS) presented data from the RemIND trial at the European Academy of Allergy and Clinical Immunology, EAACI, Congress showing that Rhapsido met its primary endpoints across the three most…
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Basel, June 12, 2026 – Novartis today presented data from the RemIND trial at the European Academy of Allergy and Clinical Immunology (EAACI) Congress showing that Rhapsido® (remibrutinib) met its pr...
Is Novartis AG (NVS) Overvalued After 3.9% Rally? GF Value Says Overvalued
Is Novartis AG (NVS) Overvalued After 3.9% Rally? GF Value Says Overvalued
Novartis says rare muscle disease drug shows promise in early trial
Novartis said on Thursday an experimental drug, which it acquired as part of its $12 billion takeover of Avidity, showed promise in an early-to-mid-stage study in patients with a type of genetic mu...
Novartis (NVS) Partners with Orionis Biosciences, Boosts Molecular Glue Drug Interest
Novartis (NVS) Partners with Orionis Biosciences, Boosts Molecular Glue Drug Interest
Market Outlook: Apple, Novartis, Rio Tinto stand out on momentum trends
Shiraz Ahmed discusses Apple, Novartis and Rio Tinto, highlighting momentum trends and long-term opportunities in technology, healthcare and commodities.
Novartis Phase 1/2 FORTITUDE Biomarker Cohort Met Primary Endpoint For Del-brax In Treatment Of FSHD
(RTTNews) - Novartis AG (NOVN.SW) announced on Thursday that the biomarker cohort of the Phase 1/2 FORTITUDE trial for Del-brax met the primary and secondary endpoints in treating Facioscapulohumeral ...
Novartis (NVS) Achieves Key Milestones in Muscle Dystrophy Treatment Study
Novartis (NVS) Achieves Key Milestones in Muscle Dystrophy Treatment Study
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect...
Novartis announces biomarker cohort in study of del-brax met primary endpoint
Novartis (NVS) announced that the biomarker cohort of the Fortitude Phase I/II study of del-brax met its primary and key secondary endpoints, with reductions in KHDC1L and creatine kinase biomarker…
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous resul...
Novartis (NVS) Teams Up with Orionis Biosciences for Drug Development
Novartis (NVS) Teams Up with Orionis Biosciences for Drug Development
Novartis, Orionis enter collaboration for molecular glue medicines
Orionis Biosciences announced a multi-year collaboration with Novartis (NVS) to discover and design molecular glue drugs for challenging therapeutic targets across multiple disease areas. The collabor...
Orionis Biosciences Announces Strategic Collaboration with Novartis to Discover and Develop Molecular Glue Medicines
BOSTON & GHENT, Belgium--(BUSINESS WIRE)--Orionis Biosciences, a privately held, clinical-stage life sciences company pioneering proximity-induced therapeutic modalities, today announced a multi-year ...
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido® (remibrutinib) clinical trial...
Novartis AG (NVS) Shares Surge 3.3% -- What GF Score of 81 Tells Investors
Novartis AG (NVS) Shares Surge 3.3% -- What GF Score of 81 Tells Investors
Novartis (NVS) Shows Promising Phase III ALIGN Study Results for Kidney Treatment
Novartis (NVS) Shows Promising Phase III ALIGN Study Results for Kidney Treatment
Novartis Vanrafia Data Show Clinically Meaningful Kidney Protection In IgA Nephropathy
(RTTNews) - Novartis AG (NVS) reported final results from the Phase III ALIGN study showing that Vanrafia slowed kidney function decline over 2.5 years in adults with IgA nephropathy (IgAN). The findi...
Novartis reports final 2.5-year Phase III ALIGN results on Vanrafia
Novartis (NVS) reported final 2.5-year Phase III ALIGN results showing slower kidney function decline with Vanrafia versus placebo in adults with IgA nephropathy. Results were published in The Lancet ...
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Basel, June 4, 2026 – Novartis reported final 2.5-year Phase III ALIGN results showing slower kidney function decline with Vanrafia® (atrasentan) versus placebo in adults with IgA nephropathy (IgAN)1 ...
Novartis Cosentyx Shows Sustained Remission In Polymyalgia Rheumatica
(RTTNews) - Novartis AG (NVS) announced new Phase III data for Cosentyx in polymyalgia rheumatica, published in the New England Journal of Medicine and presented at the 2026 EULAR Congress. The result...
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
Basel, June 3, 2026 – Novartis presented today new Cosentyx® (secukinumab) data in polymyalgia rheumatica (PMR) demonstrating a statistically significant, clinically meaningful difference in sustained...